Kestra Medical Technologies Q1 Fiscal 2027 Earnings: Revenue Beats $31.0 Million

Kestra Medical Technologies reported Q1 FY2027 revenue of $31.0M, beating estimates by $1.4M, but GAAP EPS loss widened to $0.75. Revenue grew 60% YoY, gross margin expanded to 56.5%, and FY2027 guidance was raised to $141.0M. Net loss increased to $44.1M, and cash burn rose. The stock initially fell but later gained 4.74%.

Original reporting
Published Sep 23, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kestra Medical Technologies Q1 Fiscal 2027 Earnings: Revenue Beats $31.0 Million — source image
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The earnings release was already public; this article provides no new data, serving as a summary.

02

Market read

Recap of earnings; limited actionable insight for traders.

03

What to watch

Potential impact of upcoming regulatory approvals for its defibrillator platform is not discussed.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

Kestra Medical Technologies reported Q1 FY2027 results with 60% revenue growth but widened losses and raised FY2027 guidance to $141M.

Company-level read

Ticker impact

$KMTSNeutralHigh confidence
Context

Recaps Q1 FY2027 earnings already released nine days earlier, quoting revenue, loss, and guidance.

Expected impact

Limited short-term impact; traders may hold existing positions.

Evidence & confidence

The article repeats previously disclosed numbers without fresh information.

Market effects

Wearable cardiac monitoring sector sees continued revenue growth but profitability remains pressured.

No specific regional effect beyond the company's existing market.

Limited; the story is company‑specific.

Counterpoint

Without new guidance or operational changes, the stock may be over‑valued on growth expectations.

Key entities

  • Brian Webster

    President and CEO of Kestra Medical Technologies, quoted in the release.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.